A special program in Moscow led to 100 clinical drug trial projects over two years, involving 23 Russian and foreign companies, according to Deputy Mayor Anastasia Rakova. She noted that the ecosystem established in the capital, centered around a communication hub, has effectively supported research across 15 therapeutic areas. As part of the program, a total of 36 studies focused on bioanalogs and generics, 50 studies dedicated to original drugs, and 14 studies oriented toward vaccines were initiated.
The drugs being developed are intended to treat a wide range of serious diseases, including ankylosing spondylitis, melanoma, lung and cervical cancer, and multiple sclerosis. As of September 2024, of the total number of applications, 78 were sent for organizational support, 16 for financial assistance, and 6 applications included both types of support. Four pharmaceutical companies have applied for funding for 22 clinical trials, of which 11 projects have already received approval from the Clinical Committee with the allocation of more than 42 million rubles, and 5 applications are under consideration.
